Truist Securities Downgrades Forte Biosciences to Hold
Truist Securities analyst Nicole Germino downgrades Forte Biosciences (NASDAQ:FBRX) from Buy to Hold.
Forte Biosciences Just Plummeted 80%: Here’s Why
A biopharmaceutical company focused on the development of dermatology treatments saw a sharp drop after hours Thursday.
Forte Biosciences Announces The Clinical Trial Of FB-401 For The Treatment Of Atopic Dermatitis Failed To Meet Statistical Significance
Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ:FBRX), a clinical-stage biopharmaceutical company, today announced that topline data from its Phase 2 clinical trial of FB-401 for the treatment of atopic dermatitis
66 Biggest Movers From Yesterday
Gainers
Virpax Pharmaceuticals, Inc. (NASDAQ: VRPX) shares surged 265.5% to close at $15.35 on Tuesday after the company received a written pre-investigational new drug (pre-IND) response from the FDA regarding MMS019.
48 Stocks Moving In Tuesday’s Mid-Day Session
Gainers
Virpax Pharmaceuticals, Inc. (NASDAQ: VRPX) shares jumped 93% to $$8.10 after the company received a written pre-investigational new drug (pre-IND) response from the FDA regarding MMS019.
25 Stocks Moving in Tuesday’s Pre-Market Session
Gainers
Cardiol Therapeutics Inc. (NASDAQ: CRDL) shares rose 25.8% to $3.27 in pre-market trading after dropping around 7% on Monday.